CRIS Current Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
ItalianoARDIZZONI, ANDREA
Dettaglio
ARDIZZONI, ANDREA
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE
Docenti di ruolo di Ia fascia
Pubblicazioni
Risultati 1 - 20 di 295 (tempo di esecuzione: 0.0 secondi).
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File | |
|---|---|---|---|---|---|---|---|
| 1 | 11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series | Graziani, Tiziano; Ceci, Francesco; Castellucci, Paolo; Polverari, Giulia; Lima, Giacomo Maria; L...odi, Filippo; Morganti, Alessio Giuseppe; Ardizzoni, Andrea; Schiavina, Riccardo; Fanti, Stefano | 2016 | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 1.01 Articolo in rivista | - | |
| 2 | 11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel | Ceci, F; Castellucci, P; Graziani, T; Schiavina, R; Renzi, R; Borghesi, M; Di Tullio, P; Brunocil...la, E; Ardizzoni, A; Fanti, S | 2016 | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 1.01 Articolo in rivista | - | |
| 3 | 18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results | Polverari, G; Ambrosini, V; Gelsomino, F; Diodato, S; Ceci, F; Sperandi, F; Ardizzoni, A; Fanti, S | 2016 | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 4.02 Riassunto (Abstract) | - | |
| 4 | ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC) | Morgensztern, Daniel*; Cobo, Manuel; Ponce Aix, Santiago; Postmus, Pieter E.; Lewanski, Conrad R....; Bennouna, Jaafar; Fischer, Jürgen R.; Juan-Vidal, Oscar; Stewart, David J.; Fasola, Gianpiero; Ardizzoni, Andrea; Bhore, Rafia; Wolfsteiner, Marianne; Talbot, Denis C.; Jin Ong, Teng; Govindan, Ramaswamy | 2018 | CANCER | 1.01 Articolo in rivista | - | |
| 5 | Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer | Nizzoli R; Tiseo M; Gelsomino F; Bartolotti M; Majori M; Ferrari L; De Filippo M; Rindi G; Silini... EM; Guazzi A; Ardizzoni A | 2011 | JOURNAL OF THORACIC ONCOLOGY | 1.04 Replica / breve intervento (e simili) | - | |
| 6 | ACTIVITY AND SAFETY OF DOSE-ADJUSTED INFUSIONAL CHOP CHEMOTHERAPY WITH RITUXIMAB (DA-POCH-R) IN VERY ELDERLY PATIENTS WITH POOR-PROGNOSTIC UNTREATED DIFFUSE LARGE B-CELL NON-HODGKIN'S LYMPHOMA | Boggiani D; Musolino A; Panebianco M; Franciosi V; Vasini G; Salvagni S; Ardizzoni A | 2010 | ANNALS OF ONCOLOGY | 1.06 Abstract in rivista | - | |
| 7 | Activity and Safety of Dose-Adjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With Poor-Prognostic Untreated Diffuse Large B-Cell Non-Hodgkin Lymphoma | Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A | 2011 | CANCER | 1.04 Replica / breve intervento (e simili) | - | |
| 8 | Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma | Di Federico A.; Filippini D.M.; Sperandi F.; Ardizzoni A.; Melotti B. | 2021 | EUROPEAN JOURNAL OF CANCER | 1.01 Articolo in rivista | - | |
| 9 | Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer | Livi, Vanina; Ardizzoni, Andrea; Cancellieri, Alessandra; Natali, Filippo; Ferrari, Marco; Paioli..., Daniela; De Biase, Dario; Capizzi, Elisa; Tallini, Giovanni; Fiorentino, Michelangelo; Trisolini, Rocco | 2019 | THE CLINICAL RESPIRATORY JOURNAL | 1.01 Articolo in rivista | - | |
| 10 | Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study | Barni, Sandro; Maiello, Evaristo; Di Maio, Massimo; Ardizzoni, Andrea; Cappuzzo, Federico; Maranz...ano, Ernesto; Novello, Silvia; Bennati, Chiara; Ori, Alessandra; Rizzoli, Sara; Crinò, Lucio | 2015 | LUNG CANCER | 1.01 Articolo in rivista | - | |
| 11 | Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice? | Tiseo M; Franciosi V; Grossi F; Ardizzoni A | 2006 | EUROPEAN JOURNAL OF CANCER | 1.04 Replica / breve intervento (e simili) | - | |
| 12 | Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study | Gridelli, Cesare; de Marinis, Filippo; Ardizzoni, Andrea; Novello, Silvia; Fontanini, Gabriella; ...Cappuzzo, Federico; Grossi, Francesco; Santo, Antonio; Cortinovis, Diego; Favaretto, Adolfo; Lorusso, Vito; Galetta, Domenico; Siena, Salvatore; Bettini, Anna; Iurlaro, Monica; Caprioli, Alberto; LIFE study team, Null | 2014 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 1.01 Articolo in rivista | - | |
| 13 | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): An open-label randomised controlled phase 3 trial | Soria, Jean-Charles; Felip, Enriqueta; Cobo, Manuel; Lu, Shun; Syrigos, Konstantinos; Lee, Ki Hye...ong; Göker, Erdem; Georgoulias, Vassilis; Li, Wei; Isla, Dolores; Guclu, Salih Z.; Morabito, Alessandro; Min, Young J.; Ardizzoni, Andrea; Gadgeel, Shirish M.; Wang, Bushi; Chand, Vikram K.; Goss, Glenwood D. | 2015 | THE LANCET ONCOLOGY | 1.01 Articolo in rivista | - | |
| 14 | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial | Goss G.D.; Cobo M.; Lu S.; Syrigos K.; Lee K.H.; Goker E.; Georgoulias V.; Isla D.; Morabito A.; ...Min Y.J.; Ardizzoni A.; Bender S.; Cseh A.; Felip E. | 2021 | ECLINICALMEDICINE | 1.01 Articolo in rivista | - | |
| 15 | ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients | Bozzetti, Cecilia; Nizzoli, Rita; Tiseo, Marcello; Squadrilli, Anna; Lagrasta, Costanza; Buti, Se...bastiano; Gasparro, Donatello; Zanoni, Daniele; Majori, Maria; De Filippo, Massimo; Mazzoni, Francesca; Maddau, Cristina; Naldi, Nadia; Sammarelli, Gabriella; Frati, Caterina; Pinto, Carmine; Ardizzoni, Andrea | 2015 | DIAGNOSTIC CYTOPATHOLOGY | 1.01 Articolo in rivista | - | |
| 16 | ALK rearrangement testing by fish analysis in non-small-cell lung cancer patients: Results of the first Italian external quality assurance scheme | Marchetti, Antonio; Barberis, Massimo; Papotti, Mauro; Rossi, Giulio; Franco, Renato; Malatesta, ...Sara; Buttitta, Fiamma; Ardizzoni, Andrea; Crinò, Lucio; Gridelli, Cesare; Taddei, Gian Luigi; Clemente, Claudio; Scagliotti, Giorgio; Normanno, Nicola; Pinto, Carmine | 2014 | JOURNAL OF THORACIC ONCOLOGY | 1.01 Articolo in rivista | - | |
| 17 | Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience | Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F. | 2020 | EXPERT OPINION ON BIOLOGICAL THERAPY | 1.01 Articolo in rivista | - | |
| 18 | Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding | Dall'Olio, Filippo Gustavo; Sperandi, Francesca; Rihawi, Karim; Gargiulo, Mauro; Melotti, Barbara...; Brocchi, Stefano; Gelsomino, Francesco*; Ardizzoni, Andrea | 2018 | JOURNAL OF THORACIC ONCOLOGY | 1.01 Articolo in rivista | - | |
| 19 | ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic NonâSmall Cell Lung Cancer (NSCLC) | Cho, Byoung Chul; Kim, Dong-Wan; Bearz, Alessandra; Laurie, Scott A.; Mckeage, Mark; Borra, Glori...a; Park, Keunchil; Kim, Sang-We; Ghosn, Marwan; Ardizzoni, Andrea; Maiello, Evaristo; Greystoke, Alastair; Yu, Richard; Osborne, Karen; Gu, Wen; Scott, Jeffrey W.; Passos, Vanessa Q.; Lau, Yvonne Y.; Wrona, Anna | 2017 | JOURNAL OF THORACIC ONCOLOGY | 1.01 Articolo in rivista | - | |
| 20 | Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. | Goss GD, Felip E , Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D..., Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC. | 2018 | JAMA ONCOLOGY | 1.01 Articolo in rivista | - |
Copyright © 2022